Interview: CrystalGenomics set to license lead project as research partnerships grow
12 February 2010
Ian Haydock
Please Login to read the full article.
12 February 2010
Ian Haydock
ian.haydock@informa.com
CrystalGenomics is hoping to strike a licensing agreement this year for its lead in-house development project, a next-generation COX-2 inhibitor.
The South Korean drug discovery company's alliances have so far focused on basic research, rather than product, collaborations with partners, including...
Please Login to read the full article.
RELATED CONTENT
NEWS
- CrystalGenomics beats tough market to raise $20mn in new funding
- Ajinomoto investigates protein-protein inhibitors in discovery alliance with Interprotein
- Knowledge and diversity the watchwords for Roche's early research
- Invida acquisition a big boost to Menarini's Asian presence
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
